The ‘totality-of-the-evidence’ approach in the development of PF-06438179/GP1111, an infliximab biosimilar, and in support of its use in all indications of the reference product...

por McClellan, Joseph E., Conlon, Hugh D., Bolt, Michael W., Kalfayan, Vatche, Palaparthy, Rameshraja, Rehman, Muhammad I., Kirchhoff, Carol F.
Publicado 2019

A comparative study of PF‐06438179/GP1111 (an infliximab biosimilar) and reference infliximab in patients with moderate to severe active rheumatoid arthritis: A subgroup analysis

por Kameda, Hideto, Uechi, Eishi, Atsumi, Tatsuya, Abud‐Mendoza, Carlos, Kamei, Kazumasa, Matsumoto, Tsugumi, Ponce de Leon, Dario, Rehman, Muhammad I., Zhang, Min, Radominski, Sebastiao C.
Publicado 2020

Long-term Efficacy, Safety, and Immunogenicity of the Infliximab (IFX) Biosimilar, PF-06438179/GP1111, in Patients with Rheumatoid Arthritis After Switching from Reference IFX or C...

por Cohen, Stanley B., Radominski, Sebastiao C., Kameda, Hideto, Kivitz, Alan J., Tee, Michael, Cronenberger, Carol, Zhang, Min, Hackley, Sarah, Rehman, Muhammad I., von Richter, Oliver, Alten, Rieke
Publicado 2020

A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthrit...

por Cohen, Stanley B., Alten, Rieke, Kameda, Hideto, Hala, Tomas, Radominski, Sebastiao C., Rehman, Muhammad I., Palaparthy, Ramesh, Schumacher, Karl, Schmitt, Susanne, Hua, Steven Y., Ianos, Claudia, Lea Sewell, K.
Publicado 2018